Each prescription pack comes with 2 AUVI-Q auto-injectors and a trainer.19
When you prescribe through the direct delivery service, the out-of-pocket cost for your commercially insured patient is no cost at all.
Those with commercial insurance,
including those with high-deductible plans, pay $0 out of pocket* when they obtain AUVI-Q through the direct delivery service.
*Please see full terms and conditions.
Those without government or commercial insurance
who cannot afford their medicines may be eligible for support through the kaléo Cares Program.
To be eligible for $0 out of pocket, commercially insured patients must be prescribed AUVI-Q through the direct delivery service, done either in your EMR system or by faxing in the completed enrollment form.
We continually strive to manufacture AUVI-Q with the highest standards in safety, precision, and consistent quality.
AUVI-Q is manufactured on an intelligent, high-tech, 100% automated robotic production line with over 100 automated quality checks on each AUVI-Q device, ensuring a streamlined and consistent production process. The automated robotic production line helps produce a consistent, high-quality product.
The AUVI-Q manufacturing process uses specially calibrated sensors and vision inspection systems to help ensure each component is assembled into AUVI-Q with precision. Every component built into each AUVI-Q has an identifier and is tracked throughout the manufacturing process.
About the size of a credit card and thickness of a cell phone, AUVI-Q fits in most pockets, small purses, and diaper bags.
Get to know the AUVI-Q voice.
AUVI-Q contains an electronic voice instruction system to help guide users through the entire epinephrine injection.11
A 2-second countdown begins after AUVI-Q is activated. Voice instructions will indicate the injection is complete, AUVI-Q will beep, and the lights will blink red. After use, seek immediate medical attention.11
A closer look at the first and only EAI with an automatic needle retraction system.
The AUVI-Q auto-retractable needle is not visible before, during, or after injection, and completes epinephrine injection in seconds.†
†Epinephrine injection is complete in less than half a second. However, users must push firmly and hold for a complete 2-second count.
To minimize the risk of injection-related injury, when administering AUVI-Q to young children and infants, the prescribing information instructs caregivers to hold the child's leg firmly in place and limit movement prior to and during injection.19
— patient leg —
Developed by Patients, for Patients®.
AUVI-Q was developed by twin brothers who grew up with life-threatening allergies, and was designed using Human Factors Engineering. Human Factors Engineering places the patient and caregiver at the center of the development process in order to design products that are easy to operate, and most importantly, help support correct and safe use.
Nurses are often on the front lines of educating patients on the proper use of their AUVI-Q epinephrine auto‑injectors. Download and share this kit with your team so you have the resources needed to support your patients.
AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.
Important Safety Information
AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.
AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.
Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.
Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You are leaving www.auvi-q.com
Please understand that AUVI-Q is not responsible for how your information is processed or used on non-AUVI-Q sites. Also note that providing links to non-AUVI-Q sites is not an endorsement of the other site by AUVI-Q or any of its employees. And finally, be aware that the privacy protection provided on our site may not be available on an external link.
All eligible patients with commercial insurance, including those with high-deductible plans, can get AUVI-Q® (epinephrine injection, USP) in 2 easy steps through the direct delivery service. To get started, simply download and fill out your information, then bring the form to your physician and/or designated retail pharmacies to complete.
Please see full terms and conditions.
Camargo CA Jr., Guana A, Wang S, Simons FER. Auvi-Q versus EpiPen: preferences of adults, caregivers, and children. J Allergy Clin Immunol Pract. 2013;1(3):266-272.e1-3.
Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075-1083.
Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9-17.
Blue Cross Blue Shield Association (BCBSA). The health of America report: childhood allergies in America. https://www.bcbs.com/the-health-of-america/reports/childhood-allergies-america. Published March 13, 2018. Accessed August 15, 2018.
Parlaman JP, Oron AP, Uspal NG, DeJong KN, Tieder JS. Emergency and hospital care for food-related anaphylaxis in children. Hosp Pediatr. 2016; 6(5):269-274.
Tang ML, Mullins R. Food allergy: is prevalence increasing? Intern Med J. 2017; Mar; 47(3):256-261.
Rudders SA, Arias SA, Camargo CA. Trends in Hospitalizations fro Food-Induced Anaphylaxis in US Children, 2000-2009. J Allergy Clin Immunol. 2014; 134(4): 960-962.
Clark S, Espinola J, Rudders SA, Banerji A, Camargo CA Jr. Frequency of US emergency department visits for food-related acute allergic reactions. J Allergy Clin Immunol. 2010;127(3):682-683.
Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384.
Kelly KJ, Kurup VP, Reijula KE, Fink JN. The diagnosis of natural rubber latex allergy. J Allergy Clin Immunol. 1994: 93(5):813-816.
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107(1):191-193.
Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327(6):380-384.
Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119(4):1016-1018.
Kim H, Fischer D. Anaphylaxis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S6
Hochstadter E, Clarke A, De Schryver S, et al. Increasing visits for anaphylaxis and the benefits of early epinephrine administration: A 4-year study at a pediatric emergency department in Montreal, Canada. J Allergy Clin Immunol. 2016;137(6):1888-1890.
Edwards ES, Edwards ET, Gunn R, Patterson P, North R. Design validation and labeling comprehension study for a new epinephrine autoinjector. Ann Allergy Asthma Immunol. 2013;110(3):189-193.
Simons FER. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol. 2007;120(3):537-540.
Motosue M, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Increasing emergency department visits for anaphylaxis, 2005-2014. J Allergy Clin Immunol Pract. 2017;5(1):171-175.e1-3.
Rudders S, Banerji A, Clark S, Camargo CA Jr. Age-related differences in the clinical presentation of food-induced anaphylaxis. J Pediatr. 2011;158(2):326-328.
Terms and Conditions
Only valid for commercially insured patients in the 50 United States and DC through the direct delivery service and/or designated retail pharmacies. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or Tricare, and where prohibited by law. OFFER IS NOT INSURANCE. Offer cannot be sold, purchased, traded, transferred, and cannot be combined with any other offer. Cash discount cards are not commercial payers and are not eligible to be used for this program. Offer provided by kaléo, and it may change at any time without notice. Call 1-877-30-AUVIQ for questions regarding offer eligibility.